Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents
通过开发自适应 PCR 仪器和按需试剂盒实现即时分子诊断
基本信息
- 批准号:9542523
- 负责人:
- 金额:$ 87.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-01 至 2019-08-31
- 项目状态:已结题
- 来源:
- 关键词:AdoptionBiological MarkersBusinessesCLIA certifiedCalibrationChemicalsClinicClinicalCommunicable DiseasesDNADNA PrimersDNA analysisDetectionDiagnosticDiagnostic testsDisease OutbreaksDissociationEscherichia coliEvaluationEventFDA approvedFailureFalciparum MalariaFluorescenceGoldHeatingHybridsImageIndividualInstitutionLabelLaboratoriesLicensingMeasurementModelingMolecular BiologyMolecular DiagnosisMonitorMycobacterium tuberculosisOpticsOrangesPerformancePeriodicityPhasePhysicians&apos OfficesPlasmodium falciparumPolymerase Chain ReactionPreparationPrimary Care PhysicianPropertyProtocols documentationReactionReagentReceiver Operating CharacteristicsRehydrationsResearchResourcesRural HealthSamplingSensitivity and SpecificitySiteSmall Business Technology Transfer ResearchTechnologyTemperatureTexas redTimeTubeTuberculosisUniversitiesVariantWalkinganalogbaseclinical diagnosticsdesigndiagnosis standardenantiomerinstrumentinstrumentationlaboratory facilitymedical specialtiesmeltingmolecular diagnosticspoint of careprototyperesponse
项目摘要
Because of its high sensitivity, polymerase chain reaction (PCR) is the gold standard for the diagnosis
of many infectious diseases, but generally only implemented in well-equipped laboratories. One of the major
roadblocks for expanding PCR to point-of-care markets is the lack of simple, robust, single tube PCR designs
which preserve its laboratory-based high sensitivity and specificity. In this Fast-Track STTR application
BioVentures, Inc. and Vanderbilt University, a nearby research institution, propose to develop a fundamentally
different PCR design, hybridization-triggered PCR (HT-PCR). It alters the way PCR cyclic amplification is
monitored and controlled, resulting in a design more suitable for underserved point-of-care markets. The HT-
PCR technology (co-invented by the applicants) meshes well with BioVentures's successful business model of
manufacturing and selling molecular biology reagents and aligns with its strategy to expand into the clinical
diagnostic market. Phase I and II Aims evaluate the feasibility and advantages of this approach with studies to
detect DNA biomarkers of three major infectious diseases.
One of the major impediments to simple, robust, single tube PCR is that an efficient amplification
reaction requires a narrow range of thermal and chemical conditions. Point-of-care settings, including walk-in
clinics, rural health outposts, and outbreak surveillance by mobile response units, generally lack the stringent
sample preparation and controlled environmental requirements available in centralized laboratories. The
fundamental limitation with all current PCR designs is that thermal cycling is controlled by pre-determined
indirect temperature measurements, yet the PCR product melting step and, more importantly, the primer
annealing step, do not always occur at the programmed temperatures. Individual reaction conditions, ambient
temperatures, and thermal calibrations create disparities between the expected hybridization state of the
product or primers and the actual hybridization state. These disparities are exacerbated in diagnostic settings
that are less equipped to precisely control environmental conditions and sample contents, leading to PCR
failure, i.e., false negatives. We propose an alternative PCR design that dynamically controls thermal cycling
by optically sensing the annealing and melting of mirror-image L-DNA surrogates of the reaction's primers and
targets. Because the properties L-DNA enantiomers parallel those of natural D-DNAs, the L-DNA reagents are
used to indicate the cycling conditions required for effective primer annealing and product melting during each
cycle without interfering with the reaction. A major advantage of this approach is that it enables hybridization-
triggered heating and cooling without the need to know reaction temperatures and times. Thus the instrument
dynamically adapts to unpredictable thermal and chemical variations. A second major advantage is that the L-
DNA surrogates of the PCR product can also be used as controls for reagent rehydration, sample preparation,
instrument performance, diagnostic threshold, and correct product formation, enabling well-controlled single-
tube analysis of DNA.
由于其高灵敏度,聚合酶链反应(PCR)是诊断的金标准
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nicholas M Adams其他文献
Nicholas M Adams的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nicholas M Adams', 18)}}的其他基金
Point-of-Care RT-PCR System to Inform COVID-19 and Respiratory Illness Decisions
护理点 RT-PCR 系统可为 COVID-19 和呼吸道疾病决策提供信息
- 批准号:
10265605 - 财政年份:2020
- 资助金额:
$ 87.81万 - 项目类别:
Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents
通过开发自适应 PCR 仪器和按需试剂盒实现即时分子诊断
- 批准号:
9924943 - 财政年份:2017
- 资助金额:
$ 87.81万 - 项目类别:
相似海外基金
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10490338 - 财政年份:2021
- 资助金额:
$ 87.81万 - 项目类别:
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10353104 - 财政年份:2021
- 资助金额:
$ 87.81万 - 项目类别:
Investigating pollution dynamics of swimming pool waters by means of chemical and biological markers
利用化学和生物标记物研究游泳池水体的污染动态
- 批准号:
21K04320 - 财政年份:2021
- 资助金额:
$ 87.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10688286 - 财政年份:2021
- 资助金额:
$ 87.81万 - 项目类别:
Novel biological markers for immunotherapy and comprehensive genetic analysis in thymic carcinoma
用于胸腺癌免疫治疗和综合遗传分析的新型生物标志物
- 批准号:
20K17755 - 财政年份:2020
- 资助金额:
$ 87.81万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10578649 - 财政年份:2019
- 资助金额:
$ 87.81万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10295141 - 财政年份:2019
- 资助金额:
$ 87.81万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10041708 - 财政年份:2019
- 资助金额:
$ 87.81万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
9776149 - 财政年份:2019
- 资助金额:
$ 87.81万 - 项目类别:
Combining biological and non-biological markers to develop a model predictive of treatment response for individuals with depression
结合生物和非生物标志物来开发预测抑郁症患者治疗反应的模型
- 批准号:
2063934 - 财政年份:2018
- 资助金额:
$ 87.81万 - 项目类别:
Studentship